Soldano Ferrone

Active 1975–2025

241
Papers
32,361
Citations
113
h-index
239
i10-index

Citations

Citations per year for Soldano Ferrone1975: 1 citations1976: 3 citations1977: 2 citations1978: 5 citations1979: 11 citations1980: 12 citations1981: 18 citations1982: 34 citations1983: 38 citations1984: 37 citations1985: 40 citations1986: 38 citations1987: 32 citations1988: 46 citations1989: 38 citations1990: 42 citations1991: 32 citations1992: 27 citations1993: 35 citations1994: 17 citations1995: 43 citations1996: 46 citations1997: 34 citations1998: 41 citations1999: 76 citations2000: 85 citations2001: 76 citations2002: 117 citations2003: 172 citations2004: 119 citations2005: 227 citations2006: 189 citations2007: 199 citations2008: 223 citations2009: 172 citations2010: 239 citations2011: 235 citations2012: 188 citations2013: 279 citations2014: 230 citations2015: 299 citations2016: 232 citations2017: 355 citations2018: 321 citations2019: 1,063 citations2020: 1,183 citations2021: 1,366 citations2022: 957 citations2023: 805 citations2024: 1,081 citations2025: 522 citations2026: 9 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,308 citing papers, 26.7% of this breakdownChina: 1,784 citing papers, 14.4% of this breakdownGermany: 807 citing papers, 6.5% of this breakdownItaly: 763 citing papers, 6.2% of this breakdownUnited Kingdom: 531 citing papers, 4.3% of this breakdownFrance: 492 citing papers, 4% of this breakdownJapan: 342 citing papers, 2.8% of this breakdownNetherlands: 339 citing papers, 2.7% of this breakdownAustralia: 312 citing papers, 2.5% of this breakdownSpain: 289 citing papers, 2.3% of this breakdownCanada: 284 citing papers, 2.3% of this breakdownIndia: 225 citing papers, 1.8% of this breakdown
0%26.7%Other 23.5%

Fields

  • Medicine48.6%
  • Immunology and Microbiology27%
  • Biochemistry, Genetics and Molecular Biology20.8%
  • Engineering1.1%
  • Neuroscience0.9%
  • Materials Science0.3%
  • Other1.3%

Topics

  • Immunotherapy and Immune Responses8.8%
  • Cancer Immunotherapy and Biomarkers8.5%
  • Immune Cell Function and Interaction8.1%
  • CAR-T cell therapy research6.2%
  • T-cell and B-cell Immunology3.6%
  • Immune cells in cancer2.6%
  • Other62.2%

Coauthors

All papers

Open in search
  1. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2017 cited by 755

  2. B7-H3: An Attractive Target for Antibody-based Immunotherapy

    Authors: , , , , , , - Clinical Cancer Research 2020 cited by 384

  3. Immunoaffinity‐based isolation of melanoma cell‐derived exosomes from plasma of patients with melanoma

    Authors: , , , , , , - Journal of Extracellular Vesicles 2018 cited by 343

  4. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres

    Authors: , , , , , , , , , , , , , , , , - EBioMedicine 2019 cited by 183

  5. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

    Authors: , , , , - Frontiers in Neuroscience 2021 cited by 148

  6. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 145

  7. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells

    Authors: , , , , - Scientific Reports 2020 cited by 191

  8. Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription

    Authors: , , , , , , , , , , , , , , , , , - Cancer Research 2019 cited by 156

  9. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling

    Authors: , , , , , , , , , , , , , , , , , , - Cancer Immunology Research 2021 cited by 77

  10. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

    Authors: , , , , , , , , , , , , , , - Science Translational Medicine 2017 cited by 291

  11. The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2020 cited by 118

  12. Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

    Authors: , , , , , , , , , , - Clinical Cancer Research 2021 cited by 81

  13. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dmitry I. Gabrilovich - Cancer Cell 2022 cited by 50

  14. Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

    Authors: , , , , , , , , , , , , - Clinical Cancer Research 2010 cited by 348

  15. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy

    Authors: , , , , , , , , , , , - Science Translational Medicine 2018 cited by 178

  16. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

    Authors: , , , , , , , , , , , , , - Cancers 2020 cited by 95

  17. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Filippos Kontos, Soldano Ferrone, Song Fan - Clinical Cancer Research 2021 cited by 59

  18. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells

    Authors: , , , , , , , , , , , , , , , , - Molecular Cancer Therapeutics 2021 cited by 83

  19. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ruslan I. Sadreyev, LaiPing Wong, Soldano Ferrone, Xinhui Wang - Nature Communications 2023 cited by 42

  20. Immunotherapy of cancer in 2012

    Authors: , , , , , - CA A Cancer Journal for Clinicians 2012 cited by 433

  21. CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

    Authors: , , , , , , , - Cancer Research 2015 cited by 263

  22. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma

    Authors: , , , , , , , , , - Pigment Cell & Melanoma Research 2011 cited by 200

  23. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma

    Authors: , , , , , , , , - Scientific Reports 2017 cited by 144

  24. Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients

    Authors: , , , , , , , , , , , , , , , , , - Nature Communications 2014 cited by 142